Download Citation
Article Source:
First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors
Mross K,
Richly H,
Fischer R,
Scharr D,
Büchert M,
et al.
(2013)
First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors.
PLOS ONE 8(12): e83232.
https://doi.org/10.1371/journal.pone.0083232